Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Corcept Therapeutics (CORT) over the last 10 years, with Q3 2025 value amounting to $120.0 million.

  • Corcept Therapeutics' Shares Outstanding (Diluted Average) rose 550.28% to $120.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.0 million, marking a year-over-year increase of 550.28%. This contributed to the annual value of $113.5 million for FY2024, which is 155.54% up from last year.
  • Per Corcept Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $120.0 million for Q3 2025, which was up 550.28% from $120.5 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Shares Outstanding (Diluted Average) registered a high of $129.7 million during Q1 2021, and its lowest value of $109.9 million during Q1 2024.
  • In the last 5 years, Corcept Therapeutics' Shares Outstanding (Diluted Average) had a median value of $115.4 million in 2023 and averaged $117.6 million.
  • Per our database at Business Quant, Corcept Therapeutics' Shares Outstanding (Diluted Average) tumbled by 1128.34% in 2022 and then soared by 901.06% in 2025.
  • Corcept Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $126.0 million in 2021, then dropped by 7.94% to $116.0 million in 2022, then dropped by 3.64% to $111.7 million in 2023, then rose by 1.56% to $113.5 million in 2024, then increased by 5.73% to $120.0 million in 2025.
  • Its last three reported values are $120.0 million in Q3 2025, $120.5 million for Q2 2025, and $119.8 million during Q1 2025.